Cefotetan

Cephalosporin Antibacterial — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Cefotetan is an ofp drug in the Cephalosporin Antibacterial class catalogued in DrugCentral. It was first approved by the FDA in 1985. DrugCentral lists 7 molecular targets, including PTGS2, MMP1 and COMT. Recorded indications include Acute gonococcal endometritis, Bacterial infection due to Klebsiella pneumoniae, Bacterial pneumonia and Bacterial septicemia.

• Approval status: ofp (first approved 1985 by the FDA).
• Drug class: Cephalosporin Antibacterial.
• Molecular targets: PTGS2, MMP1, COMT and MMP9 (7 listed in DrugCentral).
• Indications: Acute gonococcal endometritis, Bacterial infection due to Klebsiella pneumoniae, Bacterial pneumonia, Bacterial septicemia and Bacterial urinary infection and others.
• ATC code: J01DC05 (Second-generation cephalosporins).
• Molecular formula: C17H17N7O8S4; molecular weight 575.60 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (55)

• Acute gonococcal endometritis
• Bacterial infection due to Klebsiella pneumoniae
• Bacterial pneumonia
• Bacterial septicemia
• Bacterial urinary infection
• Bacteroides Endometritis
• Bacteroides Pelvic Inflammatory Disease
• Bacteroides Peritonitis
• Clostridium Peritonitis
• E. Coli Endometritis
• E. Coli Pelvic Inflammatory Disease
• E. Coli Peritonitis
• Endometritis
• Escherichia coli urinary tract infection
• Female genital tract infection
• Fusobacterium Endometritis
• Fusobacterium Pelvic Inflammatory Disease
• Haemophilus influenzae pneumonia
• Infection due to Escherichia coli
• Infection due to Staphylococcus aureus
• Infection of skin AND/OR subcutaneous tissue
• Infectious disease of abdomen
• Inflammatory Disease of Female Pelvic Organs
• Klebsiella cystitis
• Klebsiella Pneumoniae Peritonitis
• Lower respiratory tract infection
• Osteomyelitis due to Staphylococcus aureus
• Pelvic Inflammatory Disease with Neisseria Gonorrhea
• Peptococcus Endometritis
• Peptococcus Pelvic Inflammatory Disease
• + 25 more

Off-label uses (2)

• Infection of bone
• Infectious disorder of joint

Contraindications (7)

• Disease of liver
• Disorder of digestive system
• Factor II deficiency
• Hemolytic anemia
• Kidney disease
• Pseudomembranous enterocolitis
• Vitamin K deficiency

Mechanism & targets

• Established pharmacologic class: Cephalosporin Antibacterial

Molecular targets (7)

Target	Gene	Action	Activity
Prostaglandin G/H synthase 2	PTGS2	unknown	IC50 5.05
Interstitial collagenase	MMP1	unknown	IC50 4.89
Catechol O-methyltransferase	COMT	unknown	IC50 4.85
Matrix metalloproteinase-9	MMP9	unknown	IC50 4.72
72 kDa type IV collagenase	MMP2	unknown	IC50 4.49
Penicillin-binding protein 1A	pbpA	unknown	—
Bacterial penicillin-binding protein	mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1985-12-27	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
J01DC05	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Second-generation cephalosporins

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Haemolytic anaemia	75.9

Chemical structure

• Molecular formula: C₁₇H₁₇N₇O₈S₄
• Molecular weight: 575.60 g/mol
• CAS number: 69712-56-7
• InChIKey: SRZNHPXWXCNNDU-IXOPCIAXSA-N
• PubChem CID: 53025

CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Cefotetan used for?

DrugCentral lists the following indications for Cefotetan: Acute gonococcal endometritis, Bacterial infection due to Klebsiella pneumoniae, Bacterial pneumonia, Bacterial septicemia, Bacterial urinary infection, Bacteroides Endometritis, Bacteroides Pelvic Inflammatory Disease and Bacteroides Peritonitis and others.

How does Cefotetan work?

Its molecular targets in DrugCentral include PTGS2, MMP1, COMT and MMP9.

When was Cefotetan first approved?

Cefotetan was first approved by the FDA in 1985.

What drug class does Cefotetan belong to?

Cefotetan is in the Cephalosporin Antibacterial class.

What is the chemical formula of Cefotetan?

Cefotetan has the molecular formula C17H17N7O8S4 and a molecular weight of 575.60 g/mol.

Sources

• DrugCentral drug card 547 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201098 — compound record and bioactivity
• PubChem CID 53025 — chemical identifiers
• DrugBank DB01330 — drug record
• FDA UNII 48SPP0PA9Q — substance identity
• DailyMed: FDA labels for Cefotetan — current prescribing information (label search)
• UniProt P35354 (PTGS2) — target protein
• UniProt P03956 (MMP1) — target protein
• UniProt P21964 (COMT) — target protein
• UniProt P14780 (MMP9) — target protein
• UniProt P08253 (MMP2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.